Status:
UNKNOWN
How the Precise Habitats Can Predict the IDH Mutation Status and Prognosis of the Patients With High-grade Gliomas
Lead Sponsor:
Weiguo Zhang
Conditions:
High-grade Glioma
Eligibility:
All Genders
18+ years
Brief Summary
High-grade glioma is the most common primary malignant tumor in central nervous system, and its high tumor heterogeneity is the main cause of tumor progression, treatment resistance and recurrence. Ha...
Detailed Description
This is a single center experiment. The subjects of this study were patients diagnosed as high-grade glioma by multiparametric magnetic resonance imaging and pathological biopsy from January 1, 2008 t...
Eligibility Criteria
Inclusion
- Inclusion Criteria (if we will predict the molecular status and overall survival):
- the patient was over 18 years old
- the lesion was located in the supratentorial space;
- a histopathologic diagnosis of HGGs according to the WHO CNS4/5;
- all subjects were the first diagnosed cases without any invasive or non-invasive treatment;
- access to the complete preoperative MR imaging examinations, at least including four conventional sequences.
- Inclusion Criteria (if we will differentiate recurrence from distant intracranial recurrence):
- the patient was over 18 years old;
- the lesion was located in the supratentorial space;
- a histopathologic diagnosis of HGGs according to the WHO CNS4/5;
- underwent concurrent chemoradiotherapy with temozolomide after surgical resection or biopsy;
- underwent preoperative and postoperative MRI, at least including four conventional sequences;
- had newly appeared or enlarging, measurable, contrast-enhancing mass which raises clinical suspicion of tumor recurrence and distant intracranial recurrence;
- adequate follow-up examinations to determine treatment response on clinic-radiological consensus or pathologic confirmation.
- Exclusion Criteria:
- patient with other brain tumors or other grade gliomas at the same time;
- patient with severe basic diseases at the same time;
- patient with a survival time of less than 30 days, which can be caused by severe surgical trauma stress;
- poor image quality and heavy artifact affect the subsequent image processing.
Exclusion
Key Trial Info
Start Date :
August 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2024
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04908267
Start Date
August 1 2022
End Date
December 31 2024
Last Update
January 11 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Radiology, Daping Hospital of Army Medical University
Chongqing, Chongqing Municipality, China, 400042